Carcinoid tumors and pancreatic endocrine tumors (PETs) are uncommon neuroendocrine neoplasms and their genetic alterations are not well characterized. CpG island methylation is a mechanism of gene silencing, and concordant methylation of multiple CpG islands as CpG island methylator phenotype (CIMP) has been described in tumors. The aim of this study was to evaluate CIMP in carcinoid tumors and PETs. We studied 16 carcinoid tumors, 11 PETs, and 22 associated normal mucosa or pancreas. Methylation status of the p14, p16, cyclooxygenase 2 (COX2), O 6 -methyl-guanine methyltransferase (MGMT), estrogen receptor (ER), thrombospondin 1 (THBS1), retinoic acid receptor beta 2 (RARb), T-type calcium channel (CACNA1G), and multiple endocrine neoplasia type-1 (MEN1) genes, and of MINT1, MINT2, MINT25, MINT27 and MINT31 loci was evaluated by methylation-specific-PCR (MSP) or combined bisulfite restriction analysis (COBRA). Carcinoid tumors were frequently methylated at RARb, MGMT, p16, COX2, p14, THBS1, and ER ranging from 25 to 63% of tumors. Other CpG islands were infrequently methylated or unmethylated. The adjoining normal mucosa was also methylated for ER, COX2, and RARb, but methylation at p14, p16, THBS1, and MGMT was tumor-specific. By contrast, PETs and normal pancreas were frequently methylated only at ER. Methylation was more frequent in carcinoid tumors than PETs at MGMT (25 versus 0%, P ¼ 0.03), THBS1 (44 versus 9%, P ¼ 0.04), p14 (44 versus 9%, P ¼ 0.04) and RARb (25 versus 0%, P ¼ 0.03). Loss of p16 protein expression correlated with methylation of p16 gene in carcinoid tumors (P ¼ 0.006). Our study indicates that methylation profile of carcinoid tumors differs from PETs, reflecting different molecular pathogenesis.
Introduction
Carcinoid tumors of the gastrointestinal tract and pancreatic endocrine tumors (PETs) are both rare, indolent neuroendocrine neoplasms with an age-adjusted annual incidence of 1-2 per 100 000 population per year (Godwin, 1975) . Both types of neoplasms may secrete neuropeptides with clinical manifestations, and prognosis cannot be reliably predicted from histopathological assessment.
Multiple endocrine neoplasia type-1 (MEN1) is an autosomal dominantly inherited disorder characterized by the development of multiple endocrine tumors including carcinoid tumors and PETs (Marx, 1999) . MEN1 results from germline mutations of MEN1, a 10-exon gene located on chromosome 11q13 that encodes for menin, a 610-amino-acid protein (Calender, 1999; Jensen, 1999; Rindi et al., 1999a, b) . Mutations of the MEN1 gene and allelic loss of chromosome 11q13 also are reported in sporadic carcinoid tumors and sporadic PETs (Go¨rtz et al., 1999) .
p16 (INK4a, MTS1) tumor suppressor gene, located at chromosome 9p21, is altered in a wide variety of human malignancies by homozygous/heterozygous deletion, mutation and CpG island methylation of the promoter region (Ruas and Peters, 1998) . Homozygous deletion and methylation of p16 gene are present in PETs (Weber and Jensen, 1996; Serrano et al., 2000) . Other genetic alterations, including alterations of K-ras and p53 genes that are commonly present in other epithelial malignancies of the gastrointestinal tract, are infrequent in carcinoid tumors or PETs (Weber and Jensen, 1996; Rindi et al., 1999a) .
Recent studies have shown that methylation of CpG islands is another molecular defect which is commonly present in a wide variety of malignancies (Toyota et al., 1999a (Toyota et al., ,b, 2001 Baylin et al., 2001) . CpG islands are 0.5-2 kb kilobase regions rich in cytosine-guanine dinucleotides and are present in the 5 0 region of about half of all human genes (Bird, 1986) . Hypermethylation of the promoter region of genes including tumor suppressor genes, has been reported to be responsible for gene silencing. CpG island methylator phenotype (CIMP) is characterized by methylation of multiple CpG islands (Toyota et al., 1999a (Toyota et al., ,b, 2001 . In the present study, we studied carcinoid tumors and PETs for methylation of 14 genes and loci that are frequently methylated in other gastrointestinal malignancies. Our panel included tumor suppressor genes such as p14 (Raus and Peters, 1998; Esteller et al., 2000) , p16 (Herman et al., 1995; Esteller et al., 2000) and multiple endocrine neoplasia-1 (MEN1) genes; cancer-associated genes including cyclo-oxygenase 2 (COX2, Toyota et al., 2000) , O 6 -methyl-guanine methyltransferase (MGMT, Esteller et al., 1999) , estrogen receptor (ER, Ahuja et al., 1998) , thrombospondin 1 (THBS1, Li et al., 1999) , retinoic acid receptor beta 2 (RARb, Virmani et al., 2000; Widschwendter et al., 2000) , and T-type calcium channel (CACNA1G, Toyota et al., 1999c) genes; and CpG islands including MINT1, MINT2, MINT 25, MINT27, and MINT31 (Toyota et al., 1999a (Toyota et al., ,b, 2001 ).
Materials and methods

Characteristics of specimens and patients
Fresh tissue was collected from surgical resection specimens of carcinoid tumors or PETs in the Department of Pathology at the M. D. Anderson Cancer Center. The patient and tumor characteristics are tabulated in Table 1 . The histopathology was reviewed and the tumors were classified as carcinoid tumors and PETs using established criteria including immunohistochemical studies to detect the expression of hormones (Solcia et al., 1997; Capella et al., 2000) . The neoplastic and normal tissue were dissected from a frozen block after reviewing a hematoxylin-and eosin-stained slide. The neoplastic cellularity was 50-70%. Neoplastic tissue was available from 16 patients with carcinoid tumors and 11 patients with PETs. Normal mucosa or pancreas adjacent to the primary tumor were available from 11 patients with carcinoid tumors and all patients with PETs, and normal tissue from adjoining liver or lymph node was analysed from the remaining five patients with carcinoid tumors. The functional status of tumor was ascertained by serum measurements of hormones and/or clinical syndrome due to hormonal hypersecretion. The M. D. Anderson Cancer Center Surveillance Committee (institutional review board) approved this study.
DNA extraction, bisulfite treatment of DNA, and methylation specific-polymerase chain reaction (MSP)
DNA from both normal and tumor tissues were microdissected and extracted from fresh-frozen tissues using a commercial kit (Qiagen DNA extraction kit, Qiagen Inc., Valencia, CA, USA). Methylation of p14 and p16 was determined by bisulfite treatment of DNA followed by MSP (Herman et al., 1996) . In brief, 2 mg of microdissected genomic DNA was denatured with 2 m NaOH at 371C for 10 min, followed by incubation with 3 m sodium bisulfite (pH 5.0) at 501C for 16 h in darkness. After treatment, DNA was purified using the DNA Cleanup Kit (Promega) as recommended by the manufacturer, incubated with 3 m NaOH at room temperature for 5 min, precipitated with 10 m ammonium acetate and 100% ethanol, washed by 70% ethanol, and finally resuspended in 20 ml of distilled water. The primers and PCR conditions for p14 and p16 were the same as previously reported (Herman et al., 1996; Esteller et al., 2000) . Briefly, 2 ml of bisulfite-treated DNA was used as template for PCR reactions using primers specific for methylated and unmethylated alleles. The colon cancer cell line RKO (American Type Culture Collection, Manasas, VA, USA) and water were used as positive and negative controls, respectively. PCR products from methylated and unmethylated reaction, were electrophoresed on 6% acrylamide gels and visualized by ethidium bromide staining.
Combined bisulfite restriction analysis (COBRA)
The methylation status of the MINT1, MINT2, MINT25, MINT27, and MINT31 CpG island loci, as well as the promoter CpG islands of COX2, MGMT, ER, THBS1, RARb, MEN1, and CACNA1G genes was determined by COBRA as previously described (Xiong and Laird, 1997) . For the PCR reaction 2 ml of bisulfite-treated DNA was used as template.
The primers and cycling conditions of the markers used in this study are listed in Table 2 . To avoid overestimation of the methylated alleles, the following points were considered. First, primers were designed to contain a minimum number of CpG dinucleotides in the sequence to avoid biased amplification of methylated alleles. If primers contained CpG sites, they were designed to amplify methylated and unmethylated alleles equally (with a mixture of C or T used for sense primers, and a mixture of G or A for antisense primers). Second, the primers were designed to contain a maximum number of thymidines converted from cytosines to avoid amplifying the unconverted genomic sequence. Third, amplification from genomic DNA without bisulfite treatment was carried out initially to monitor absence of nonspecific amplification. The colon cancer cell lines RKO and SW48 (American Type Culture Collection, Manasas, VA, USA) and water were used as positive and negative controls, respectively. After amplification, 50-80% of the PCR products were digested with restriction enzymes as described previously (Xiong and Laird, 1997) and electrophoresed in nondenaturing polyacrylamide gels. The gels were stained with ethidium bromide, and the proportion of methylated allele was evaluated by densitometry. COBRA for MEN1 gene was performed by amplifying a 225 bp PCR product encompassing 5 0 untranslated region, exon 1 and intron 1 that had two BstUI sites (Figure 1 ). The methylation status of MEN1 gene was confirmed by PCR amplification using the primers used for COBRA followed by DNA sequencing of representative normal mucosa and pancreas, tumor samples, and RKO and SW48 cell lines. DNA treated with SssI methylase (CpG methylase; New England Biolabs Inc., Beverly, MA, USA) using the buffer and conditions supplied by the manufacturer was used as positive control.
Loss of heterozygosity (LOH) of chromosome 9p Loss of chromosome 9p was determined by using four dinucleotiderepeat microsatellite markers on the short arm of chromosome 9 (D9S161, D9S171, D9S259, D9S285). LOH was determined by fluorescent labeled PCR amplification using fluorescent dye-labeled and unlabeled primers (Applied Biosystems, Foster City, CA, USA). The 5 0 oligonucleotide was end-labeled with 6-FAM (D9S161, D9S259), or NED (D9S171, D9S285) fluorescent dye. PCR was performed in 15 ml reaction volumes containing 40 ng of DNA, 9 ml ABI Prism s True Allele t PCR Premix (Applied Biosystems, Foster City, CA, USA), and 5 pmol of each primer. PCR was carried out using the following cycling conditions: denaturation at 951C for 12 min; 10 cycles (941C for 15 s, 551C for 15 s, 721C for 30 s), 32 cycles (891C for 15 s, 551C for 15 s, 721C for 30 s), and extension at 721C for 10 min. A 1.0 ml aliquot of each fluorescent-labeled PCR product was combined with 12 ml of formamide and 0.5 ml Genescan s 400HD [ROX] size standard (Applied Biosystems, Foster City, CA, USA). The samples were then capillary electrophoresed on an ABI 3700 DNA Analyzer using GeneScan s Analysis software (Applied Biosystems, Foster City, CA, USA).
Complete or partial loss of chromosome 9p was based on the pattern of loss of the four dinucleotide microsatellite markers. Loss of a marker was considered to be present when the PCR assay showed absence or decrease in intensity by more than 50% of a band from a tumor sample as compared with the paired control non-neoplastic sample.
Sequencing of b-catenin and p16 b-catenin gene was sequenced as previously described (Rashid et al., 2001) . Exons 1, 2, and 3 of the p16 gene were amplified by genomic PCR. Exon 1 of the p16 gene was amplified using the forward and reverse amplification primers 5 0 -CGGA-GAGGGGGAGAGCAG-3 0 and 5 0 -TCCCCTTTTTCCGGA-GAATCG-3 0 , respectively. The cycling conditions were: 951C for 10 min, 42 cycles of 951C for 1 min and 601C for 1 min. Exon 2 of the p16 gene was amplified using the forward and reverse amplification primers 5 0 -CGGTGAGGGGGCTCTA-CACAAG-3 0 and 5 0 -GCTGAACTTTCTGTGCTGGAAA-ATG-3 0 , respectively. The cycling conditions were: 951C for 10 min, 40 cycles of 951C for 30 s and 681C for 45 s.
Exon 3 of the p16 gene was amplified using the forward and reverse amplification primers 5 0 -AGAACTTTATCCATAAG-TATTTC-3 0 and 5 0 -GTGACTGATGATCTAAGTTTC-3 0 , respectively. The cycling conditions were: 951C for 5 min, 40 cycles of 951C for 30 s and 551C for 1 min.
DNA sequencing was performed using the first PCR product and amplification primers using a commercial DNA sequencing kit according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). The forward and reverse primers for sequencing were 5 0 -CGGAGAGGGGGA-GAGCAG-3 0 and 5 0 -TCCCCTTTTTCCGGAGAATCG-3 0 for exon 1; 5 0 -CGGTGAGGGGGCTCTACACAAG-3 0 and 5 0 -GCTGAACTTTCTGTGCTGGAAAATG-3 0 for exon 2; and primers used for amplifying for exon 3, respectively. Germline mutations were excluded by sequencing DNA extracted from adjoining normal tissue.
Immunohistochemistry for p16
Immunohistochemistry for p16 was performed using a p16 monoclonal antibody (F12; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) as previously described (Konishi et al., 2002) . Sections (5 mm) of formalin-fixed, paraffin-embedded tissue were cut onto coated slides and baked overnight in 601C oven. The section was deparaffinized by routine techniques, and incubated with primary antibody diluted to 200 ng/ml at 41C overnight. Labeling was detected with the DAKO 
Statistical analysis
All statistical analysis was performed using SPSS (SPSS Inc., Chicago, IL, USA). Student's t-test or Fisher's exact test was used to compare the means of intensity of methylation between normal and neoplastic tissue at each locus, and associations between methylation and various clinicopathological factors. Samples containing more than 5% methylated alleles compared to unmethylated alleles were arbitrarily designated as methylated, whereas samples containing less than 5% methylated alleles compared to unmethylated alleles were designated unmethylated. Correlation among methylation densities of the various genes was measured by means of Spearman rank order correlation coefficient.
Results
We analysed the methylation status of a panel of CpG islands associated with nine genes and five loci in 16 carcinoid tumors, 11 PETs and 22 normal mucosa or pancreas adjacent to the primary site of the tumor. Examples of assay are shown in Figure 2 and the results are summarized in Figures 3 and 4 .
CpG island methylation (CIM) in carcinoid tumors
Of the 14 loci examined in 16 carcinoid tumors, ER, p14, THBS1, p16, COX2, RARb, and MGMT genes were frequently methylated; MINT27 and MINT31 were occasionally methylated, and MEN1 and CACNAIG genes and MINT2 and MINT25 loci were unmethylated in all samples (Figures 3a and 4 ). Methylation at individual loci was 63% (10 of 16) for ER, 44% (7 of 16) for p14 and THBS1, 31% (5 of 16) for p16 and COX2, 25% (4 of 16) for RARb and MGMT, and 6% (1 of 16) for MINT2 and MINT25, respectively. The normal mucosa adjacent to the primary carcinoid tumors was methylated at ER, RARb, and COX2 genes and MINT1 locus (Figures 3a and 4) . ER gene was methylated in 56% (6 of 11) samples (four samples from ileum and two from colon); RARb gene in 27% (3 of 11) samples (one sample from ileum and two from colon); COX2 gene in 18% (2 of 11) samples (one sample from duodenum and one from ileum), and MINT1 in 27% (3 Figure 2 (a) Methylation-specific-PCR for p16 and p14 genes using unmethylated (U) and methylated (M) primers. Sample numbers and molecular weight (MW) is on the top of the lanes. Sample 1 is methylated and samples 2-4 are unmethylated for p16; and samples 1 and 3 are methylated and samples 2 and 4 are unmethylated for p14. (b) Combined bisulfite restriction analysis (COBRA) for ER, MGMT, MINT27, MINT31, THBS1, RARb, and MINT1. Sample numbers and molecular weight (MW) is on the top of the lanes. Unmethylated alleles after restriction enzyme digest for genes and loci analysed by COBRA are indicated by an arrow, and methylated alleles by an arrowhead. Methylated alleles by COBRA are present in samples 1, 3, 4, and 7 for ER; samples 2, 5, and 7 for MGMT; sample 1 for MINT27; sample 1 for MINT31; samples 4 and 6 for THBS1; samples 1, 2, 6 and 9 by RARb; and samples 1, 2, 3, 7, and 8 for MINT1 of 11) samples (one sample from ileum and two from colon).
A CpG-rich area is present at the 5 0 region of the MEN1 gene encompassing 5 0 untranslated region, exons 1 and 2 and the intervening intron (Figure 1 ). However, MEN1 was unmethylated in all tumor samples, normal mucosa or pancreas, or colon cancer cell lines by COBRA. DNA sequencing of representative amplified PCR products confirmed conversion of all cytosines to thymidines due to bisulfite treatment of unmethylated cytosines. Methylated cytosines were present in DNA treated by Sss 1 methylase, but not in PCR products from normal mucosa or pancreas, tumor samples, or colon cancer cell lines (data not shown).
The methylation density of tumor tissue was compared to adjacent normal mucosa and methylation for p14, THBS1, p16, and MGMT genes were tumorspecific (P ¼ 0.04 for p14 gene, P ¼ 0.006 for THBS1 gene, P ¼ 0.01 for p16 gene, and P ¼ 0.04 for MGMT gene). By contrast, methylation for ER, RARb and COX2 genes, and MINT1, MINT27, and MINT31 loci were not tumor specific.
When concordant methylation was evaluated, methylation at the p16 gene correlated with methylation at other genes, and loci: MINT27 (r ¼ 0.5, P ¼ 0.005), MINT31 (r ¼ 0.4, P ¼ 0.04), COX2 (r ¼ 0.6, P ¼ 0.002), ER (r ¼ 0.6, P ¼ 0.002), and RARb (r ¼ 0.3, P ¼ 0.01). The distribution of methylation was bimodal, and the tumors methylated at p14 or p16 were also more frequently methylated at other genes and loci (2.871.8 genes or loci methylated versus 1.071.1 for tumors unmethylated at p14 or p16; P ¼ 0.02).
CpG island methylation (CIM) in PETs
Of the 14 loci examined in 11 PETs, ER gene was methylated in 64% (seven of 11) samples, MINT1 and MINT31 were methylated in 18% (two of 11) samples, p14, p16, THBS1 and COX2 genes and MINT27 were methylated in 9% (one of 11) samples, and MEN1, CACNAIG, RARb and MGMT genes, and MINT2 and MINT25 loci were unmethylated in all samples ( Figures  3b and 4) .
In adjoining normal pancreas, methylation was present at ER and COX2 genes, and MINT1, MINT 27 and MINT31 loci (Figures 3b and 4) . ER gene and MINT1 were methylated in 27% (three of 11) samples, MINT27 in 18% (two of 11) samples, and COX2, and MINT31 in 9% (one of 11) samples.
The methylation density of normal pancreatic tissue was compared to PETs and methylation for all genes 
Comparison of methylation in carcinoids and PETs
The pattern of methylation differed between carcinoid tumors and PETs (Figures 3 and 4) . MGMT gene was methylated in 25% (four of 16) of carcinoid tumors versus 0% (zero of 11) of PETs (P ¼ 0.04), p14 gene in 44% (seven of 16) versus 9% (one of 11, P ¼ 0.04), THBS1 gene in 44% (seven of 16) versus 9% (one of 11, P ¼ 0.04), and RARb gene in 25% (four of 16) versus 0% (zero of 11, P ¼ 0.01).
Association of CpG island methylation and clinicopathological factors
CpG island methylation at p16 and ER correlated with patient age. The mean age of patients whose carcinoid tumors had p16 methylation was 74.076.9 years, compared to 59.1713.1 years for those without p16 methylation (P ¼ 0.01). Similarly, the mean age of patients whose carcinoid tumors were methylated at ER gene was 69.877.8 years, compared to 53.3715.5 years for those without ER methylation (P ¼ 0.03). In contrast, ER methylation in PETs showed a trend toward inverse relationship to age. The mean age of patients whose PETs were methylated at ER gene was 50.0721.0 years, compared to 61.579.8 years for those without ER methylation but the difference was not statistically significant.
Liver metastasis was uncommon in patients with PETs and was present in only 18% (2 of 11) patients with PETs but 56% (nine of 16) patients with carcinoid tumors (P ¼ 0.04). Methylation at p16 was related to metastatic status in patients with carcinoid tumors. Methylation of the p16 gene also was present in 45% (five of 11) patients with carcinoid tumors or pancreatic endocrine tumors metastatic to liver versus 6% (one of 6) patients without (P ¼ 0.01).
Loss of chromosome 9p in carcinoid tumors and PETs
Chromosome 9p loss was present in 18% (2 of 11) of PETs, and in none of 16 carcinoid tumors (Figure 4) . The loss was present at the locus 9p21-23 (markers D9S161, D9S259, and D9S285) in one patient and at the locus 9p22-23 (marker D9S285) from another patient. These two cases had no methylation at any of the loci.
Mutation of b-catenin and p16 genes
No b-catenin or p16 gene mutations were present in any carcinoid tumors or PETs. Two patients with carcinoid tumors had alanine (GCG) to threonine (ACG) polymorphism at cordon 148, exon 2 of p16 gene in tumor and normal tissues.
Relation Between p16 Gene Alterations and expression of p16
The relation between p16 gene alterations and its protein expression was examined in 14 carcinoid tumors and 10 PETs by immunohistochemical staining with an antip16 monoclonal antibody ( Figure 5 ). Of these, 33% (four of 12) carcinoid tumors and 10% (one of 10) PETs were methylated at p16 gene, 20% (two of 10) PETs had chromosome 9p loss, and the remaining carcinoid tumors and PETs showed no alterations of p16 gene. Overall, loss of nuclear staining for p16 was present in 50% (seven of 14) carcinoid tumors and 50% (five of 10) PETs. The loss of p16 expression correlated with p16 alteration status and was present in 80% (four of five) carcinoid tumors with methylation of p16 gene compared to 33% (three of nine) carcinoid tumors without methylation (P ¼ 0.006). Similarly, loss of p16 expression was present in 100% (one of one) PETs with methylation of p16 gene and 50% (one of two) PETs with chromosome 9p loss compared to 43% (3 of 7) PETs without alterations of p16 gene.
Discussion
We found that p14, p16, MGMT, and THBS1 genes were frequently methylated in carcinoid tumors but were not methylated in PETs. In contrast, ER gene was frequently methylated in carcinoid tumors, PETs, and normal tissue; and RARb and COX2 genes were methylated in carcinoid tumors and adjacent normal tissue.
The CDKN2D/p14 gene, which shares a portion of the CDKN2A/p16 coding region, has a unique first exon 1b originating 20 kb centromeric to CDKN2A/p16 exon 1. This exon, under the control of its own promoter, splices onto exon 2 of CDKN2A/p16 in an alternative reading frame, allowing the production of two totally unrelated proteins (Serrano et al., 1996) . In our study, methylation of p14 and p16 gene was present in 43 and 31% of carcinoid tumors, respectively, and 9 and 9% of PETs, respectively, but no p16 gene mutations were present. Muscarella et al. (1998) have reported methylation of p16 gene in 58% of gastrinomas and nonfunctional PETs, but no p16 gene mutation. Of note, in contrast to the previous study, most of the PETs in the present study were not metastatic. In the present study, an association between liver metastasis and p16 methylation in carcinoid tumors was present. Recently, Lubomierski et al. (2001) , showed that tumor suppressor genes localized in the 9p21 gene cluster are specific targets of inactivation in carcinoid tumors and PETs. Loss of expression of p14, p15, and p16 is present in carcinoid tumors and nonfunctional PETs, and a human PET cell line, and demethylating treatment reversed p15 and p16 silencing with concurrent growth restraint. Thus, p14, p15, and p16 genes are methylated in carcinoid tumors and PETs and may have an important role in tumorigenesis.
In our study, no b-catenin mutation was present in carcinoid tumors or PETs, in contrast to a previous study that reported frequent b-catenin gene mutation in carcinoid tumors (Fujimori et al., 2001) .
THBS1 is a known angiogenesis inhibitor whose altered expression is associated with neovascularization in human cancers (Roberts, 1996) . Hypermethylation of the THBS1 promoter and an associated decrease of THBS1 expression were reported in several carcinoma cell lines, primary brain tumors, and colon cancers (Roberts, 1996; Li et al., 1999) . Methylation frequency of THBS1 in carcinoid tumors is higher than reported in other tumors. COX2 is the rate-limiting enzyme for the production of prostanoids (prostaglandins and thromboxanes) from arachidonic acid. In recent years, strong evidence has emerged that COX2 is causally involved in colorectal carcinogenesis. COX-2 expression is increased in colorectal cancers and adenomatous polyps (Eberhart et al., 1994; Oshima et al., 1996) , and in gastric cancers (Ristimaki et al., 1997; Lim et al., 2000; Uefuji et al., 2000) . MGMT is a DNA repair gene for guanosine methyl adducts that is frequently inactivated in lymphomas and in colon, lung, and brain tumors (Esteller et al., 1999) . A growing body of evidence supports the hypotheses that the RAR gene is a tumor suppressor gene (Roman et al., 1992; Swisshelm et al., 1994; Seewaldt et al., 1995) . RARb expression is reduced in many malignant tumors. Epigenetic silencing of RAR by methylation has been suggested to play important role in lung and breast cancer (Virmani et al., 2000; Widschwendter et al., 2000) . The presence of methylation in these genes suggested these might be important targets in carcinoid tumorigenesis. On the other hand, although mutation of the MEN1 gene has been shown to be an important mechanism in PET carcinogenesis, but methylation at this gene does not seem to play an important role.
In previous studies of methylation in colorectal and gastric cancers, MINT1, MINT2, MINT27, and MINT31 were frequently methylated (Toyota et al., 1999a,b) , but were rarely methylated in carcinoid tumors or PETs in the present study. Similarly, MINT25 was frequently methylated in gastric cancer (Toyota et al., 1999b) but was not methylated in the two gastric carcinoids, other carcinoid tumors or PETS in this study. Similarly, a previous study (Ueki et al., 2000) of methylation in pancreatic carcinomas reported more frequent methylation of p16, RARb, and CACNA1G genes, and MINT1, MINT2, and MINT31 loci than in PETs in our study. In contrast, THBS1 gene was infrequently methylated and MGMT gene was not methylated in pancreatic carcinomas and PETs. ER gene was methylated in normal and tumor tissues. In contrast, ER gene was methylated in three of four carcinoid tumors from stomach and duodenum, but was unmethylated in normal tissues from these sites. This is corroborated by previous studies that have reported that ER is not tumor-specific in colorectum (Ahuja et al., 1998) , but is tumor-specific in esophagus (Eads et al., 2001) . Similarly, the carcinoid tumors of lung are infrequently methylated compared to other lung tumors but RASSFIA gene is frequently methylated in carcinoid tumors (Toyooka et al., 2001) . These data suggest that frequency of methylation and loci that are methylated vary in an organ-and tumor-specific manner in normal and tumor tissues.
Our study demonstrated several molecular differences in carcinoid tumors and PETs: p14, THBS1, and MGMT genes were methylated in carcinoid tumors but not PETs; and loss of chromosome 9p was found exclusively in PET. As has been previously pointed out (Jensen, 1999; Mignon, 2000) , although carcinoid tumor and PET share a number of similarities, it is important that these two groups of tumors continue to be analysed separately rather than combined together. Not only are these two general groups of tumors functionally different, but they also may differ in biologic behavior in terms of metastatic spread and aggressiveness. The findings in our study further support the concept that these two groups of tumor are fundamentally different and the carcinogenic process evolves along two different pathways.
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